Impossible Foods

Investor appetite for alternative meats grow amid concerns of food safety and security - THE EDGE SINGAPORE

F&B sector

Investor appetite for alternative meats grows amid concerns of food safety and security

For something dubbed "fake meat", the investment potential is quite real.
Temasek sows US$10 million seed funding into plant-based chickens - THE EDGE SINGAPORE

Startups, Entrepreneurs, Digital economy

Temasek sows US$10 million seed funding into plant-based chickens

Plant-based meat is expected by UBS Group AG to be worth more than US$51 billion by 2025.

Food & Beverage

Jet-setters and local guests can now enjoy Violet Oon's dishes at Jewel Changi

SINGAPORE (July 24): Award-winning culinary doyenne Violet Oon has devoted her life to curating great food in Singapore and even at 70 years old, she still shows no signs of stopping. She recently received the Lifetime Achievement for Outstanding Contribu

Startups, Entrepreneurs, Digital economy

Singapore first in Asia to taste food made from spirulina algae

SINGAPORE (June 26): Following the footsteps of companies like Impossible Foods and Beyond Meat, Israeli startup Simpliigood wants you to eat its food products made from spirulina – a type of algae. And Singapore will be its first market in Asia.

Equity raising

Temasek-backed Impossible Foods raises US$300 mil in latest Series E funding

SINGAPORE (May 14): Impossible Foods announced that it has raised US$300 million ($410.5 million) in its latest Series E funding round, led by existing investors Temasek and Horizon Ventures.


Beyond rich: Billion-dollar faux meat movement overlooks the hungry half

SINGAPORE (May 6): On May 2, the maker of what is essentially fake meat raised US$241 million ($328.36 million) in an IPO on Nasdaq. California-based Beyond Meat sold 9.63 million shares at US$25 each, the top of the pricing range. The listing gives the 1

Food & Beverage

From lab to table

Clever marketing and big money have combined to attract some consumers to meat replacements grown in labs. Is mass-market appeal a matter of time or an impossible feat?